Haixia Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haixia Su has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Yechun Xu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
10 shared publications - Leike Zhang
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science
7 shared publications Hang Xie
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 China
6 shared publicationsMinjun Li
Shanghai Synchrotron Radiation Facility Shanghai Advanced Research Institute Chinese Academy of Sciences Shanghai 201204 China
6 shared publicationsTianqing Nie
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 China
5 shared publications- Hong Liu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
4 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e12342
Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors
Recurrence of coronavirus outbreaks and zoonotic origins of human coronaviruses underscore the importance of developing pan‐coronavirus antivirals. The highly conserved 3C‐like protease (3CL pro ) in coronaviruses, together with the well‐established druggability, makes it an ideal target for broad‐spectrum antiviral therapeutics. Here, the inhibitory activity of approved 3CL pro inhibitors, including nirmatrelvir, ensitrelvir, and simnotrelvir, against fifteen 3CL pro s is first reported by enzymatic assays. Despite their potent inhibition toward 3CL pro s of β‐CoVs, these inhibitors show reduced potency against 3CL pro s from the other three genera, particularly against two newly identified human coronaviruses (α‐CCoV‐HuPn‐2018 and δ‐PDCoV). In this context, continued efforts in structure‐based optimization of nirmatrelvir lead to the identification of compound 8 that potently inhibits a panel of 32 3CL pro s across all subgenera (IC 50 s: 19–146 n m ), with an IC 50 value of 61 and 81 n m against α‐CCoV‐HuPn‐2018 and δ‐PDCoV 3CL pro s, respectively. Moreover, it effectively inhibits nirmatrelvir‐resistant 3CL pro mutants and demonstrates broad‐spectrum antiviral efficacy in cells. These findings suggest an important rule that a small, non‐cyclic P2 segment and a P4 segment with a suitable size are preferred by the design of ultra‐broad‐spectrum 3CL pro inhibitors, and provide a proof‐of‐concept guide for developing broad‐spectrum antivirals as potential pan‐CoV therapeutics.
- 12 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e12342
Open AccessStructure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors
Recurrence of coronavirus outbreaks and zoonotic origins of human coronaviruses underscore the importance of developing pan‐coronavirus antivirals. The highly conserved 3C‐like protease (3CL pro ) in coronaviruses, together with the well‐established druggability, makes it an ideal target for broad‐spectrum antiviral therapeutics. Here, the inhibitory activity of approved 3CL pro inhibitors, including nirmatrelvir, ensitrelvir, and simnotrelvir, against fifteen 3CL pro s is first reported by enzymatic assays. Despite their potent inhibition toward 3CL pro s of β‐CoVs, these inhibitors show reduced potency against 3CL pro s from the other three genera, particularly against two newly identified human coronaviruses (α‐CCoV‐HuPn‐2018 and δ‐PDCoV). In this context, continued efforts in structure‐based optimization of nirmatrelvir lead to the identification of compound 8 that potently inhibits a panel of 32 3CL pro s across all subgenera (IC 50 s: 19–146 n m ), with an IC 50 value of 61 and 81 n m against α‐CCoV‐HuPn‐2018 and δ‐PDCoV 3CL pro s, respectively. Moreover, it effectively inhibits nirmatrelvir‐resistant 3CL pro mutants and demonstrates broad‐spectrum antiviral efficacy in cells. These findings suggest an important rule that a small, non‐cyclic P2 segment and a P4 segment with a suitable size are preferred by the design of ultra‐broad‐spectrum 3CL pro inhibitors, and provide a proof‐of‐concept guide for developing broad‐spectrum antivirals as potential pan‐CoV therapeutics.
- Open Access
- 8 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Structure-based design of potent and selective inhibitors targeting RIPK3 for eliminating on-target toxicity in vitro
The essential role of RIPK3 in necroptosis makes its inhibition a promising therapeutic strategy. However, the development of RIPK3 inhibitors has been hampered by on-target apoptosis and limited kinase selectivity. Inspired by the R69H mutation, which prevents on-target apoptosis by disrupting RIPK3 dimerization, we design LK-series inhibitors that effectively inhibit RIPK3 in biochemical assays and block TNF-α-induced necroptosis in both mouse L929 and human HT29 cells without inducing apoptosis. The representative compound, LK01003, shows high selectivity across a panel of 379 kinases. Our structural studies reveal that LK compounds act as Type I1/2 inhibitors, engaging a unique hydrophobic site and stabilizing an inactive conformation of RIPK3. Moreover, several type II inhibitors are also revealed to maintain RIPK3 in the inactive conformation and do not induce on-target apoptosis. These findings suggest a promising strategy for rational design of safe and selective inhibitors by locking the inactive conformation of RIPK3.
- 8 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessStructure-based design of potent and selective inhibitors targeting RIPK3 for eliminating on-target toxicity in vitro
The essential role of RIPK3 in necroptosis makes its inhibition a promising therapeutic strategy. However, the development of RIPK3 inhibitors has been hampered by on-target apoptosis and limited kinase selectivity. Inspired by the R69H mutation, which prevents on-target apoptosis by disrupting RIPK3 dimerization, we design LK-series inhibitors that effectively inhibit RIPK3 in biochemical assays and block TNF-α-induced necroptosis in both mouse L929 and human HT29 cells without inducing apoptosis. The representative compound, LK01003, shows high selectivity across a panel of 379 kinases. Our structural studies reveal that LK compounds act as Type I1/2 inhibitors, engaging a unique hydrophobic site and stabilizing an inactive conformation of RIPK3. Moreover, several type II inhibitors are also revealed to maintain RIPK3 in the inactive conformation and do not induce on-target apoptosis. These findings suggest a promising strategy for rational design of safe and selective inhibitors by locking the inactive conformation of RIPK3.
- 29 April 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 161, 108503
Identification of RIPK3 as a target of flavonoids for anti-necroptosis in vitro
- 29 April 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 161, 108503
Identification of RIPK3 as a target of flavonoids for anti-necroptosis in vitro
- 22 November 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 264, 115984
Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3
- 22 November 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 264, 115984
Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3
- Open Access
- 13 October 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-2
Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
- 13 October 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-2
Open AccessCorrection: Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
- 23 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115512
Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2
- 23 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115512
Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2
- Open Access
- 22 May 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
- 22 May 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Open AccessDiscovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
- Open Access
- 11 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8633
Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
The papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a critical role in the proteolytic processing of viral polyproteins and the dysregulation of the host immune response, providing a promising therapeutic target. Here, we report the structure-guide design of novel peptidomimetic inhibitors covalently targeting SARS-CoV-2 PLpro. The resulting inhibitors demonstrate submicromolar potency in the enzymatic assay (IC50 = 0.23 μM) and significant inhibition of SARS-CoV-2 PLpro in the HEK293T cells using a cell-based protease assay (EC50 = 3.61 μM). Moreover, an X-ray crystal structure of SARS-CoV-2 PLpro in complex with compound 2 confirms the covalent binding of the inhibitor to the catalytic residue cysteine 111 (C111) and emphasizes the importance of interactions with tyrosine 268 (Y268). Together, our findings reveal a new scaffold of SARS-CoV-2 PLpro inhibitors and provide an attractive starting point for further optimization.
- 11 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8633
Open AccessStructure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
The papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a critical role in the proteolytic processing of viral polyproteins and the dysregulation of the host immune response, providing a promising therapeutic target. Here, we report the structure-guide design of novel peptidomimetic inhibitors covalently targeting SARS-CoV-2 PLpro. The resulting inhibitors demonstrate submicromolar potency in the enzymatic assay (IC50 = 0.23 μM) and significant inhibition of SARS-CoV-2 PLpro in the HEK293T cells using a cell-based protease assay (EC50 = 3.61 μM). Moreover, an X-ray crystal structure of SARS-CoV-2 PLpro in complex with compound 2 confirms the covalent binding of the inhibitor to the catalytic residue cysteine 111 (C111) and emphasizes the importance of interactions with tyrosine 268 (Y268). Together, our findings reveal a new scaffold of SARS-CoV-2 PLpro inhibitors and provide an attractive starting point for further optimization.
- 9 May 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 87, 117316
Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety
- 9 May 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 87, 117316
Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety
- Open Access
- 28 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 190
Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.
- 28 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 190
Open AccessDiscovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.